5.27

7.11% +0.35

After Hours: 5.56 0.29 +5.50%

Prime Medicine Inc (PRME)

Overview News Price History Option Chain Discussions Forecast

Prime Medicine Inc stock is currently priced at $5.27, with a 24-hour trading volume of 802.92K. It has seen a +7.11% increased in the last 24 hours and a -22.04% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.89 pivot point. If it approaches the $5.37 resistance level, significant changes may occur.

Previous Close:

$4.92

Open:

$4.88

24h Volume:

802.92K

Market Cap:

$632.55M

Revenue:

Net Income/Loss:

$-198.13M

P/E Ratio:

-2.8508

EPS:

-1.8486

Net Cash Flow:

$-174.14M

1W Performance:

+12.13%

1M Performance:

-22.04%

6M Performance:

-17.91%

1Y Performance:

-62.38%

1D Range:

$4.85

$5.59

52W Range:

$4.11

$17.20

Prime Medicine Inc Stock (PRME) Company Profile

Name

Prime Medicine Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

617 564 0013

Address

21 Erie Street, Cambridge

Employee

175

Twitter

Next Earnings Date

Latest SEC Filings

PRME's Discussions on Twitter

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-23	Initiated	Guggenheim	Buy
Apr-18-23	Initiated	Stifel	Buy
Nov-14-22	Initiated	Goldman	Neutral
Nov-14-22	Initiated	JP Morgan	Overweight
Nov-14-22	Initiated	Jefferies	Buy
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight

View All

Prime Medicine Inc Stock (PRME) Latest News

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

GlobeNewswire Inc.

2 Magnificent Growth Stocks With Room to Run

The Motley Fool

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire Inc.

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire Inc.

Prime Medicine Announces Pricing of Upsized Public Offering

GlobeNewswire Inc.

Prime Medicine Announces Proposed Public Offering of Common Stock

GlobeNewswire Inc.

Prime Medicine Inc Stock (PRME) Financials Data

Prime Medicine Inc (PRME) Net Income 2024

PRME net income (TTM) was -$198.13 million for the quarter ending December 31, 2023, a -62.64% decrease year-over-year.

Prime Medicine Inc (PRME) Cash Flow 2024

PRME recorded a free cash flow (TTM) of -$174.14 million for the quarter ending December 31, 2023, a -17.72% decrease year-over-year.

Prime Medicine Inc (PRME) Earnings per Share 2024

PRME earnings per share (TTM) was -$2.18 for the quarter ending December 31, 2023, a -17.60% decline year-over-year.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.